Federal Register of Legislation - Australian Government

Primary content

PB 103 of 2009 Specifications as made
This Specification amends the National Health Act (Pharmaceutical Benefits - Early Supply) - specification under subsection 84AAA(2) Instrument 2009 (No. PB 30 of 2009) to determine pharmaceutical benefits that can be resupplied inside 20 days on the one prescription.
Administered by: Health
Registered 29 Oct 2009
Tabling HistoryDate
Tabled HR16-Nov-2009
Tabled Senate16-Nov-2009
Date of repeal 19 Mar 2014
Repealed by Health (Spent and Redundant Instruments) Repeal Regulation 2014

 

COMMONWEALTH OF AUSTRALIA

Instrument number PB 103 of 2009

National Health (Pharmaceutical Benefits – Early Supply) Amendment November 2009 - Specification Under Subsection 84AAA(2)

 

Amendment determination under subsection 84AAA(2) of the National Health Act 1953

 

I, Linda Jackson, Assistant Secretary, Pharmaceutical Evaluation Branch, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.

 

Dated          16     October 2009

Linda Jackson

 

LINDA JACKSON

Assistant Secretary

Pharmaceutical Evaluation Branch

Department of Health and Ageing

 

 

 

Amendment determination — Pharmaceutical Benefits-Early Supply

 

 

1          Name of Instrument

 

(1)           This Instrument is the National Health Act (Pharmaceutical Benefits – Early Supply) Amendment November 2009 - specification under subsection 84AAA(2).

 

(2)           This Instrument may also be cited as “No. PB 103 of 2009”.


 

2          Commencement

 

This Instrument commences on 1 November 2009.

 

 

3          Amendment of PB 30 of 2009

 

Schedule 1 amends the National Health (Pharmaceutical Benefits – Early Supply) Instrument 2009, PB 30 of 2009.

 


Schedule 1        Amendments

[1]                                  Schedule 1, item dealing with Etanercept

omit from the column headed “Form (strength, type, size, etc.):

Injection 50 mg in 1 mL single use injection pen, 4

 

and substitute:

Injection 50 mg in 1 mL single use auto-injector, 4

 

[2]                                  Schedule 1, before item dealing with Ezetimibe with Simvastatin, Tablet 10 mg-40 mg

insert in the columns in the order indicated:

 

 

Tablet 10 mg-10 mg

Oral

30

5

 

Tablet 10 mg-20 mg

Oral

30

5

 

 

[3]                                  Schedule 1, item dealing with Lansoprazole

omit from the columns in the order indicated:

 

 

Capsule 30 mg

Oral

30

5

 

Sachet containing granules for oral suspension, 30 mg per sachet

Oral

28

5

 

 

[4]                                  Schedule 1, after item dealing with Valsartan with hydrochlorothiazide, Tablet 160 mg-25 mg

insert in the columns in the order indicated:

 

 

Tablet 320 mg-12.5 mg

Oral

28

5

 

Tablet 320 mg-25 mg

Oral

28

5